Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Supernus Pharmaceuticals Inc shares valued at $1,919,868 were purchased by JACK A. KHATTAR on Oct 01 ’25. At $47.79 per share, JACK A. KHATTAR acquired 40,173 shares.
Also, Khattar Jack A. sold 8,588 shares, netting a total of over 414,371 in proceeds. Following the sale of shares at $48.25 each, the insider now holds 1,147,258 shares.
Before that, JACK A. KHATTAR had added 8,588 shares to its account. In a trade valued at $408,789, the Director bought Supernus Pharmaceuticals Inc shares for $47.60 each.
As published in a research note from Cantor Fitzgerald on July 30, 2025, Supernus Pharmaceuticals Inc [SUPN] has been rated up from a Neutral to an Overweight and the price target has been revised to $42. Analysts at Cantor Fitzgerald downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid February. As of January 06, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for SUPN. Earlier on September 11, 2024, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for SUPN stock which previously was a “an Overweight”.
Analyzing SUPN Stock Performance
On last trading session, Supernus Pharmaceuticals Inc [NASDAQ: SUPN] rose 0.52% to $48.04. The stock’s lowest price that day was $47.32, but it reached a high of $48.27 in the same session. During the last five days, there has been a surge of approximately 2.00%. Over the course of the year, Supernus Pharmaceuticals Inc shares have jumped approximately 56.23%. Shares of the company reached a 52-week high of $48.44 on 09/30/25 and a 52-week low of $29.16 on 05/07/25.
Support And Resistance Levels for Supernus Pharmaceuticals Inc (SUPN)
According to the 24-hour chart, there is a support level at 47.46, which, if violated, would cause prices to drop to 46.89. In the upper region, resistance lies at 48.44. The next price resistance is at 48.85. RSI (Relative Strength Index) is 70.72 on the 14-day chart, showing overbought technical sentiment.
Is Supernus Pharmaceuticals Inc subject to short interest?
Stocks of Supernus Pharmaceuticals Inc saw a sharp rise in short interest on 2025-09-15 jumping by 0.32 million shares to 5.02 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 4.7 million shares. A jump of 6.35% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.69 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.69.
Which companies own the most shares of Supernus Pharmaceuticals Inc (SUPN)?
In terms of Supernus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 51.5 in the next 12 months, up nearly 7.76% from the previous closing price of $47.79. Analysts anticipate Supernus Pharmaceuticals Inc stock to reach 63 by 2025, with the lowest price target being 40. In spite of this, 3 analysts ranked Supernus Pharmaceuticals Inc stock as Buy at the end of 2025. On January 03, 2023, Jefferies assigned a price target of “a Buy” to the stock and resumed coverage with a $45.
